Study ID |
Imatinib Dose |
No. of Patients, Age,66 Sex |
GIST Tumor Characteristics |
Outcomes Sought |
N |
%CR |
%PR |
%SD |
%PD |
%NE |
%Other |
---|---|---|---|---|---|---|---|---|---|---|---|
Phase II |
|||||||||||
Bumming, 200355 |
400 mg/d |
17 |
All patients were high risk or overtly malignant GIST (metastatic disease at presentation) # of prior surgeries |
Tu response: CT RECIST or PET |
Neoadjuvant 1 |
100% (5pts) |
100% |
||||
Adjuvant 5 |
|||||||||||
Palliative 11 |
73% |
9% |
18% |
||||||||
Retrospective reviews |
|||||||||||
Rutkowski, 200356 |
400-800 mg/d |
35 |
Patients with C-KIT+ GIST that had liver metastases as documented in the database; all patients underwent surgery 57% complete resection 17% microscopically incomplete resection 26% open biopsy only |
Tu response: CT RECIST |
Surgery 3 |
||||||
Imatinib 32 |
50% |
37.5% |
12.5% |
||||||||
Scaife, 200357 |
76% 400 mg imatinib |
17 |
Unresectable intraabdominal c-KIT+ GISTS by CD117 immunohistochemisty. Patients who received imatinib pre-operatively (neo-adjuvantly) and then underwent surgical exploration for tumor resection. |
Tu response: Radiographic change on CT (criteria unclear), PET, or peri-operative
pathological specimens; |
CT: 17 |
6% |
70% |
18% |
6% |
||
PET: 17 |
55% |
27% |
2% |
0% |
|||||||
[median followup from imatinib treatment to resection = 10mo; median followup after surgery = 6mos] |
Pathology: 17 |
12% |
65% |
18% |
6% |
||||||
94% (complete resection) |
|||||||||||
Wu, 200358 |
400-800 mg/d |
57 |
Diagnosed with GIST and receiving a related surgical resection |
OS:
Kaplan- Meier |
All patients who underwent surgery, regardless of use of imatinib. |
57 |
82% complete resections | ||||
Patients who underwent surgery and were exposed to imatinib in the adjuvant (for high risk disease; N = 3) or palliative (metastatic disease at resection or relapse; N = 26) settings |
29 |
Not clearly stated |
85% with initial PR or SD |